Kintor Pharmaceutical : Pharma Roadshow Presentation

Kintor Pharma

Developing Novel Drugs and Commercialization Platform

Confidential

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by representatives Kintor Pharmaceutical Limited (the "Company", and together with its subsidiaries, the "Group") for use in presentations by the Group. No part of this presentation should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of the Company's subsidiaries, branches, affiliates, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its subsidiaries, branches, affiliates, advisors or representatives are under an obligation to update, revise or affirm.

The information communicated in this presentation may contain certain statements that are or may be forward looking. These statements typically contain words such as "will", "may", "expects", "forecasts", "plans" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward-looking statements. Neither the Company nor its subsidiaries, affiliates, advisors or representatives assume any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company or any of its subsidiaries or affiliates in any jurisdiction. Neither this presentation nor anything provided herein shall form the basis of or be relied on in connection with, or act as an inducement to enter into any contract decisions or commitment whatsoever. This presentation and the information contained herein is being furnished to you solely for your information and may not be disclosed, reproduced or redistributed to any other person, in whole or in part. In particular, no information contained in this presentation may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By attending this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group. Nothing in this presentation should be construed as regulatory, valuation, legal, tax, accounting or investment advice. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in an offering circular or prospectus prepared in relation to such offering.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are either (a) a "qualified institutional buyer" (within the meaning of Regulation 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or (b) outside of the United States. You are also deemed to have represented and agreed that you and any customer you represent are professional investors as defined in the Securities and Futures Ordinance (Cap 571 Laws of Hong Kong) and any rules made under that Ordinance.

1

Major Accomplishments Since the Beginning of 2021

9 IND applications in China and US

Proxalutamide for COVID-19 (3)

Pyrilutamide for AGA (1) ALK-1+PD-1 for HCC(1)

ALK-1+PD-L1/CTLA4 for multiple solid tumors(1)

AR-PROTAC compound for AGA and acne (2)

PD-L1/TGF-β antibody IND accepted (1)

3 registered phase III MRCTs for COVID-19 of proxalutamide

Phase III MRCT for outpatients (US & Intl)

Phase III MRCT for inpatients (US, China & Intl)

Phase III MRCT for outpatients (China, Brazil & Intl)

1 emergency use authorization

First EUA for hospitalized patients in Paraguay

3 partnerships on commercialization of proxalutamide (COVID-19)

With Fosun Pharma in India and 28 African countries

With Etana in Indonesia

With Visum regarding production capacity expansion of proxalutamide

1 clinical trial met primary endpoint

KX-826's phase II trial for male AGA adults met primary endpoints in China

The primary endpoint was the change from baseline in non-vellus TAHC at week 24 in comparison with placebo

The majority of AEs were mild and no SAE occurred

5mg (0.5%) will be used in phase III trial in China

Capital Market

Inclusion in Hang Seng Composite Index

Announced by Hang Seng Indexes Company on Aug 20

Effective date is Sep 6

First placing after IPO

Issued 18.2 million shares, which was 4.7% of total shares after placing

Net proceeds was HKD1.16 billion (USD 150 million)

Staff

New hiring of talents

New hired core management: Dr. Qun LU (CTO) responsible for CMC, and Dr. Jiawen HAN (BD VP) responsible for BD

Besides, we have hired talents in clinical medicine/operations, project management and manufacturing for enriched pipeline and commercialization

Increase in staff

Number of staff was increased to 272 as of June 30 from 202 in the beginning of 2021, with more than 50% in clinical and R&D function

2

Table of Contents

01	Company Overview
02	Investment Highlights
03	Our Strategies
04	Financial Overview

3

Section 1

Company Overview